...
首页> 外文期刊>European journal of cancer care >Percutaneous transhepatic hybrid biliary endoprostheses using both plastic and metallic stents for palliative treatment of malignant common bile duct obstruction
【24h】

Percutaneous transhepatic hybrid biliary endoprostheses using both plastic and metallic stents for palliative treatment of malignant common bile duct obstruction

机译:使用塑料和金属支架经皮经肝穿刺混合胆管假体姑息治疗恶性胆总管阻塞

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To evaluate clinical safety and efficacy of percutaneous transhepatic hybrid biliary prostheses for palliative treatment in patients with common bile duct obstruction caused by advanced malignancies. A total of 13 consecutive patients was treated with percutaneous transhepatic biliary endoprostheses concurrently using both plastic and metallic stents. Serum total bilirubin levels before and after stent placement were evaluated. The technical success rate, the period with no obstructive jaundice, patient survival and complications were also assessed. Median bilirubin levels decreased from 3.8mg/dL before to 1.2mg/dL after stent placement, and this difference was statistically significant. The median no-jaundice period after bile duct stent placement was 6.0 months (range: 2-11 months), and overall survival time was 7.0 months. Of the 13 patients, nine did not have recurrent jaundice by the time of death, whereas four (31%) had recurrent jaundice. A second intervention was performed in these four patients. A new plastic stent was placed and jaundice did not recur up to the time of death. No serious complications such as cholangitis, pancreatitis or bile duct perforation developed. Percutaneous transhepatic hybrid biliary endoprostheses using both plastic and metallic stents can be useful as non-invasive palliative treatment to relieve jaundice in patients with malignant obstructive jaundice.
机译:评价经皮肝穿刺混合肝假体在晚期恶性肿瘤引起的胆总管阻塞患者中姑息治疗的临床安全性和有效性。总共13例连续患者同时使用塑料支架和金属支架接受了经皮经肝穿刺胆管内假体的治疗。评估支架置入前后的血清总胆红素水平。还评估了技术成功率,无阻塞性黄疸的时期,患者的生存率和并发症。胆红素中位数水平从支架置入前的3.8mg / dL降至支架置入后的1.2mg / dL,这一差异具有统计学意义。胆管支架置入后的中位无黄疸期为6.0个月(范围:2-11个月),总生存时间为7.0个月。在这13例患者中,有9例在死亡时没有复发性黄疸,而4例(31%)患有复发性黄疸。对这四名患者进行了第二次干预。放置了一个新的塑料支架,直到死亡时黄疸一直没有复发。没有出现严重的并发症,如胆管炎,胰腺炎或胆管穿孔。同时使用塑料支架和金属支架的经皮肝穿刺混合胆管假体可作为非侵入性姑息治疗,以减轻恶性阻塞性黄疸患者的黄疸。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号